Since NAD+-dependent SIRT1 activity is essential for a normal metabolic function [20], treatments that target the cellular NAD+-SIRT1 axis represent a potential preventive/therapeutic intervention strategy for obesity- and aging-related metabolic disorders (Figure 2). The gene discussed is SIRT1; the disease is obesity due to melanocortin 4 receptor deficiency.